EPH161 Dose Escalation Patterns in Patients with Overweight or Obesity Initiating Semaglutide 2.4mg: A 6-Month Follow-up in a Real-World Setting in the United States

Abstract

Once-weekly subcutaneous semaglutide 2.4mg is approved for chronic weight management in adults with obesity (or overweight with ≥1 weight-related comorbidity). This study describes real-world treatment patterns of semaglutide 2.4mg for 6 months following medication initiation when availability of escalation and maintenance doses were limited.